<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017613</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530-1301</org_study_id>
    <secondary_id>2013-003769-32</secondary_id>
    <nct_id>NCT02017613</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies</brief_title>
  <acronym>PI3K</acronym>
  <official_title>A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K&#xD;
      delta/gamma inhibitor in patients with hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Maximum tolerated dose (MTD) will be determined based on the safety, pharmacokinetic (PK)&#xD;
      and efficacy data. Safety analyses include AE's, AE's related to the drug, SAE's, laboratory&#xD;
      values, vitals/ ECG and dose limiting toxicity (DLT). PK include measurement of peak plasma&#xD;
      concentration (Cmax), area under the plasma concentration versus the time curve (AUC), time&#xD;
      of maximum concentration observed (Tmax). Efficacy analyses include overall response rate&#xD;
      (ORR) and duration of response (DOR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and pharmacokinetics (PK) of RP6530</measure>
    <time_frame>28 days</time_frame>
    <description>To access maximum tolerated dose by clinical laboratory assessments, adverse events and dose limiting toxicities.&#xD;
PK parameter AUC, Cmax, tmax, t1/2 will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response following administration of RP6530</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overall response rate (ORR) and duration of response (DOR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP6530 administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP6530</intervention_name>
    <description>Escalating doses starting at 25 mg BID</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>PI3k Delta/ Gamma inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractory to or relapsed after at least 1 prior treatment line.&#xD;
&#xD;
          -  ECOG performance status ≤2&#xD;
&#xD;
          -  Patients must be ≥18 years of age&#xD;
&#xD;
          -  Able to give a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any cancer therapy in the last 4 weeks or limited palliative radiation &lt;2 weeks&#xD;
&#xD;
          -  Patients with HBV, HCV or HIV infection&#xD;
&#xD;
          -  Autologous hematologic stem cell transplant within 3 months of study entry. Allogeneic&#xD;
             hematologic stem cell transplant within 12 months.&#xD;
&#xD;
          -  Previous therapy with GS-1101 (CAL-101, idelalisib), IPI-145, TGR-1202 or any drug&#xD;
             that specifically inhibits PI3K/ mTOR (including temsirolimus, everolimus), AKT or BTK&#xD;
             Inhibitor (including Ibrutinib).&#xD;
&#xD;
          -  Patients on immunosuppressive therapy including systemic corticosteroids.&#xD;
&#xD;
          -  Patients who are receiving chronic systemic anticoagulation therapy (warfarin sodium&#xD;
             or heparin, etc.).&#xD;
&#xD;
          -  Patients with known history of liver disorders.&#xD;
&#xD;
          -  Patients with uncontrolled Diabetes Type I or Type II&#xD;
&#xD;
          -  Any severe and/or uncontrolled medical conditions or other conditions that could&#xD;
             affect their participation in the study.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale San Raffaele s.r.l.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmelo Carlo-stella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Clinical and Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Delarue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Necker-Enfants Malades</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rhizen Trial Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhizen Trial Site 1</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhizen Trial Site 2</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL, SLL, NHL, SLL, PTCL, CTCL, MM, AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

